The Interplay of Tau and Amyloid Beta Pathologies in Alzheimer's Disease
DOI:
https://doi.org/10.47611/jsrhs.v12i4.5732Keywords:
Beta-Amyloid, Alzheimer, Tau, plaques, neurofibrillary tangles, Aβ Plaques, Neurodegenerative DiseaseAbstract
Alzheimer’s is a progressive neurodegenerative disease that is associated with cognitive decline and dementia. It is characterized by the buildup of beta-amyloid (Aβ) plaques and neurofibrillary tau tangles in the brain. The Aβ plaques are formed through insoluble Aβ fragments clumping together in between neurons and blocking synaptic function. On the other hand, neurofibrillary tau tangles are formed through the misfolding of tau monomers which then accumulate within neurons. Although original research focused on the two components separately, recent research has attempted to view the interplay between Aβ and tau to figure out the impact and discover potential treatments for Alzheimer’s. A lot about Alzheimer’s is still unknown and we are still figuring out how exactly the plaques and tangles are created. Alzheimer’s currently does not have a cure, but there are FDA-approved treatments that can differ depending on the stage of Alzheimer’s. These medications are synthesized to either slow disease progression or alleviate the symptoms temporarily. The objectives of this paper are to investigate the relationship between the beta-amyloid plaques and the tau tangles, explore their combined impact, and consider the implications of their interactions that will potentially help us treat Alzheimer’s in the future.
Downloads
References or Bibliography
Spires-Jones, T. L., & Hyman, B. T. (2014). The intersection of amyloid beta and tau at synapses in Alzheimer’s disease. Neuron, 82(4), 756. https://doi.org/10.1016/j.neuron.2014.05.004
Do, T. D., Economou, N. J., Chamas, A., Buratto, S. K., Shea, J. E., & Bowers, M. T. (2014). Interactions between amyloid-β and Tau fragments promote aberrant aggregates: implications for amyloid toxicity. The journal of physical chemistry. B, 118(38), 11220–11230. https://doi.org/10.1021/jp506258g
Pasieka, A., Panek, D., Szałaj, N., Espargaró, A., Więckowska, A., Malawska, B., Sabaté, R., & Bajda, M. (2021). Dual Inhibitors of Amyloid-β and Tau Aggregation with Amyloid-β Disaggregating Properties: Extended In Cellulo, In Silico, and Kinetic Studies of Multifunctional Anti-Alzheimer's Agents. ACS chemical neuroscience, 12(11), 2057–2068. https://doi.org/10.1021/acschemneuro.1c00235
Murugan, N. A., Nordberg, A., & Ågren, H. (2018). Different Positron Emission Tomography Tau Tracers Bind to Multiple Binding Sites on the Tau Fibril: Insight from Computational Modeling. ACS chemical neuroscience, 9(7), 1757–1767. https://doi.org/10.1021/acschemneuro.8b00093
Noble, W., Hanger, D. P., Miller, C. C., & Lovestone, S. (2013). The importance of tau phosphorylation for neurodegenerative diseases. Frontiers in neurology, 4, 83. https://doi.org/10.3389/fneur.2013.00083
Crimins, J. L., Pooler, A., Polydoro, M., Luebke, J. I., & Spires-Jones, T. L. (2013). The intersection of amyloid β and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer's disease. Ageing research reviews, 12(3), 757–763. https://doi.org/10.1016/j.arr.2013.03.002
Alonso, A. D., Grundke-Iqbal, I., Barra, H. S., & Iqbal, K. (1997). Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proceedings of the National Academy of Sciences of the United States of America, 94(1), 298–303. https://doi.org/10.1073/pnas.94.1.298
Avila, J., Jiménez, J. S., Sayas, C. L., Bolós, M., Zabala, J. C., Rivas, G., & Hernández, F. (2016). Tau Structures. Frontiers in aging neuroscience, 8, 262. https://doi.org/10.3389/fnagi.2016.00262
João Pedro Ferrari-Souza, Bruna Bellaver, Pâmela Ferreira et al. APOEε4 potentiates Aβ effects on longitudinal tangle accumulation via tau phosphorylation, 20 January 2023, PREPRINT (Version 1) available at Research Square [https://doi.org/10.21203/rs.3.rs-2391695/v1]
Van Dyck, Christopher H. Swanson, Chad J, Aisen, Paul, Bateman, Randall J, Chen, Christopher, Gee, Michelle, Kanekiyo, Michio, Li, David, Reyderman, Larisa (2023). Lecanemab in Early Alzheimer’s Disease. New England Journal of Medicine 0028-4793. https://doi.org/10.1056/NEJMoa2212948
Published
How to Cite
Issue
Section
Copyright (c) 2023 Mahathi Harith
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
